scholarly journals Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

2018 ◽  
Vol 17 (1) ◽  
Author(s):  
Julio Rosenstock ◽  
◽  
Vlado Perkovic ◽  
John H. Alexander ◽  
Mark E. Cooper ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Outcome Study ◽  
Cardiovascular Safety ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Baseline Characteristics

Effectiveness of the piperine-supplemented Curcuma longa L. in metabolic control of patients with type 2 diabetes: a randomised double-blind placebo-controlled clinical trial

2021 ◽  
pp. 1-10
Author(s):  
Joana Furtado de Figueiredo Neta ◽  
Vivian Saraiva Veras ◽  
Danilo Ferreira de Sousa ◽  
Maria da Conceição dos Santos Oliveira Cunha ◽  
Maria Veraci Oliveira Queiroz ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Metabolic Control ◽  
Curcuma Longa ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

21-OR: Final Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the MetAP2 Inhibitor ZGN-1061 in Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 21-OR ◽  
Author(s):  
TERRI KIM ◽  
DONGLIANG ZHUANG ◽  
TONYA L. HAUGEN ◽  
DENNIS D. KIM ◽  
KRISTIN TAYLOR
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Phase 2 ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document